In brief
The Trump administration has announced the selection of 15 new medications for a Medicare drug price negotiation program, allowing the federal government to negotiate prices directly with drug manufacturers. The program is expected to deliver considerable savings to taxpayers by targeting some of the most expensive medications, including popular drugs for Type 2 diabetes, HIV, and arthritis. This marks a significant step towards addressing the skyrocketing prescription drug prices affecting seniors.
NEW YORK (AP) — The Medicare drug price negotiation program has selected 15 new medications for negotiation, which includes treatments primarily for Type 2 diabetes, HIV, and arthritis, as announced by the Trump administration on Tuesday. These drugs, which account for significant expenditures in the Medicare system, are expected to result in substantial savings for taxpayers once negotiations take effect in 2028.The list includes medications like the popular Type 2 diabetes drug Trulicity and the HIV medication Biktarvy, in addition to the neurotoxin Botox, used for various medical purposes. Centers for Medicare and Medicaid Services (CMS) Administrator Dr. Mehmet Oz stated that the initiative aims to show that the system works for the patients rather than for special interests, alleviating the financial burden on seniors and taxpayers alike.This move contributes to the ongoing effort to lower prescription drug prices in the U.S., with previous price negotiations also affecting widely used drugs such as Ozempic and Wegovy. With this year's selections, the program now encompasses a total of 40 drugs whose prices have been negotiated, highlighting a focused approach toward curbing the soaring prices of essential medications.The program includes drugs from both Medicare Part B and Part D, expanding the scope of negotiable medications. As the government prepares for these negotiations, stakeholders have voiced their opinions, with AARP calling it a significant step forward for older Americans in healthcare, while pharmaceutical representatives criticize the program as flawed.In conclusion, the inclusion of these 15 drugs for negotiation reflects the ongoing legislative efforts to ensure drug pricing reform, helping to protect Medicare enrollees from excessive costs associated with essential medications.
